A groundbreaking EGF-Receptor receptor tyrosine kinase blocker named targeted therapy drug has revolutionized the treatment landscape. It has become a pivotal treatment for Individuals with NSCLC (NSCLC) carrying activating EGF-Receptor mutations.For this patient population, which receives targeted therapy drug as the initial treatment, clinical studies have focused on its pivotal efficacy in extending time-to-disease-worsening (survival without disease progression).This article aims to investigate targeted therapy drug's position in achieving first-line survival without disease progression, and investigate the four vital requirements associated with its application.Need 1: The Fine-tuning of targeted therapy drug…
